ZTS · XBRL financial data

Zoetis financial statements, every fiscal year

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ZTS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	6,675	7,776	8,080	8,544	9,256	9,467
Cost of goods and services sold	2,057	2,303	2,454	2,561	2,719	2,666
Selling, general and administrative	1,726	2,001	2,009	2,151	2,318	2,378
Interest expense	231	224	221	239	225	222
Other income (expense)	(5)	(4)	14	(1)	(4)	(6)
Income tax expense (benefit)	360	454	545	596	637	687
Net income (loss)	1,638	2,037	2,114	2,344	2,486	2,673
Earnings per share, basic USD per share	3.44	4.29	4.51	5.08	5.47	6.03
Earnings per share, diluted USD per share	3.42	4.27	4.49	5.07	5.47	6.02
Weighted average shares, basic millions of shares	476	474	469	461	454	443
Weighted average shares, diluted millions of shares	479	477	470	462	455	444

Fiscal years (ZTS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	3,604	3,485	3,581	2,041	1,987	2,450
Short-term investments	—	—	—	—	—	0
Accounts receivable	1,013	1,133	1,215	1,304	1,316	1,590
Inventory	1,628	1,923	2,345	2,564	2,306	2,430
Total current assets	6,611	6,930	7,506	6,343	5,986	6,768
Property and equipment, net	2,202	2,422	2,753	3,204	3,391	3,681
Right-of-use asset	192	181	220	230	219	288
Goodwill	2,694	2,682	2,746	2,759	2,724	2,767
Total assets	13,609	13,900	14,925	14,286	14,237	15,467
Accounts payable	457	436	405	411	433	487
Accrued liabilities	556	710	682	683	746	852
Commercial paper	0	0	0	0	0	0
Current portion of long-term debt	600	0	1,350	0	1,350	0
Total current liabilities	2,170	1,797	3,167	1,889	3,412	2,235
Long-term debt	6,595	6,592	6,552	6,564	5,220	9,042
Lease liability, non-current	163	151	186	188	174	196
Total liabilities	9,836	9,356	10,522	9,295	9,467	12,136
Retained earnings	5,659	7,186	8,668	10,295	11,968	13,744
Total stockholders' equity	3,769	4,543	4,405	4,997	4,770	3,331
Total liabilities and equity	13,609	13,900	14,925	14,286	14,237	15,467
Common shares outstanding (cover page) millions of shares	475	472	463	458	448	422

Fiscal years (ZTS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,638	2,037	2,114	2,344	2,486	2,673
Stock-based compensation	59	58	62	60	74	83
Depreciation and amortization	441	448	465	491	497	487
Net cash from operating activities	2,126	2,213	1,912	2,353	2,953	2,904
Purchases of property and equipment	453	477	586	732	655	621
Net cash from investing activities	(572)	(458)	(883)	(777)	(315)	(748)
Share repurchases	250	743	1,594	1,092	1,858	3,235
Repayments of long-term debt	500	600	0	1,350	0	1,350
Net cash from financing activities	123	(1,862)	(904)	(3,109)	(2,660)	(1,870)
Net change in cash	1,670	(119)	96	(1,540)	(54)	325

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Zoetis	1,476	2,468	655*	413.2M	Q2 FY26 10-QJun 30, 2026
Regeneron Pharmaceuticals	3,659	5,116	1,783*	not reported	Q3 FY26 10-QSep 30, 2026
Bristol Myers Squibb	9,574	13,069	4,181*	2.0B	Q3 FY26 10-QSep 30, 2026
Gilead Sciences	6,437	8,300	5,035*	1.2B	Q3 FY26 10-QSep 30, 2026
Idexx Laboratories	198	1,214	450*	78.8M	Q3 FY26 10-QSep 30, 2026
Alnylam Pharmaceuticals	1,754	1,458	341*	133.9M	Q3 FY26 10-QSep 30, 2026
Vertex Pharmaceuticals	4,979	3,441	643*	253.5M	Q3 FY26 10-QSep 30, 2026
Pfizer	1,824	16,583	5,375*	5.7B	Q3 FY26 10-QSep 27, 2026
Amgen	13,190	10,365	4,241*	540.9M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.